Fierce Pharma

FEBRUARY 29, 2024

In what CEO Albert Bourla called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of antibody-dru | Pfizer on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of Seagen. The company aims to have at least eight blockbuster cancer drugs by 2030, with a focus on four main cancer types.

71

71

Pharmaceutical Technology

FEBRUARY 29, 2024

India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.

143

143

Fierce Pharma

FEBRUARY 29, 2024

As Johnson & Johnson's U.S. exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | As Johnson & Johnson's U.S. exclusivity period on Stelara ticks away, another biosimilar player has lined up for the piece of the blockbuster's sales pie.

Sales 305

Sales 305

MedCity News

FEBRUARY 29, 2024

Telehealth is great at expanding access to care, but sometimes the quality isn’t there, according to Dr. Pat Carroll, chief medical officer of Hims & Hers.

Healthcare 120

Healthcare Healthcare Medical 120

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

FEBRUARY 29, 2024

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown its staying power in older adults who received a single dose before the previous virus season. | Pfizer’s respiratory syncytial virus vaccine Abrysvo has shown its staying power in a trial of patients who received a single dose before the previous virus season. In season two, Abrysvo provided efficacy of 78% against lower respiratory tract disease in adults 60 and older, according to trial results released Thursday.

Patients 301

Patients 301

MedCity News

FEBRUARY 29, 2024

Increasing costs and healthcare cybersecurity worries have sparked calls for new laws. The bipartisan “Strengthening Cybersecurity in Health Care Act” by four senators would require the HHS to perform routine evaluations of its systems and deliver biannual reports on practices and progress.

Healthcare 119

Healthcare Healthcare 119

MedCity News

FEBRUARY 29, 2024

While the past several decades have seen progress in early detection, recent innovations in metastatic breast cancer—or cancer that has spread to distant parts of the body, including the bone, brain, or lungs—continues to cause excitement.

Biopharma 116

Biopharma 116

Fierce Pharma

FEBRUARY 29, 2024

Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers | Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers in Florida.

Manufacturing 294

Manufacturing 294

MedCity News

FEBRUARY 29, 2024

Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.

Medicine 115

Medicine Biopharma Pharma 115

Fierce Pharma

FEBRUARY 29, 2024

Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in | Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in the past.

277

277

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

FEBRUARY 29, 2024

Adopting an infinite mindset could be the antidote to the slow destruction of healthcare by short-term thinking.

Healthcare 115

Healthcare Healthcare 115

Fierce Pharma

FEBRUARY 29, 2024

For the second time in four weeks, GSK has settled a personal injury lawsuit in California sta | For the second time in four weeks, GSK has settled a personal injury lawsuit in California state court over the heartburn drug Zantac. The company revealed the dismissal of the case and the agreement in a release Thursday.

264

264

PharmaTimes

FEBRUARY 29, 2024

Aphasia is a language disorder caused by some form of brain damage, including stroke

Patients 111

Patients 111

Fierce Pharma

FEBRUARY 29, 2024

Editor's note: This story was updated to note that Endo's criminal and civil opioid settlement payments will be satisfied by the bankruptcy resolution, according to an Endo | As it looks to emerge from bankruptcy, Endo agreed to fork over up to $464.9 million to the federal government, which had been investigating the marketing of opioid Opana ER.

Government 263

Government Marketing 263

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

MedCity News

FEBRUARY 29, 2024

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

Healthcare 111

Healthcare Healthcare Medical Biopharma 111

Fierce Pharma

FEBRUARY 29, 2024

Despite a restricted FDA label, Sarepta Therapeutics has seen early commercial success with its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. | The company is quickly moving through Elevidys' eligible patient population while awaiting the FDA's decision on a broader label. In the fourth quarter, the gene therapy pulled down $131 million in sales.

FDA 203

FDA Sales Patients 203

pharmaphorum

FEBRUARY 29, 2024

Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.

107

107

Fierce Pharma

FEBRUARY 29, 2024

BeiGene expanded its global workforce by 1,400 over the past 12 months amid fast revenue growth. | BeiGene expanded its global workforce by 1,400 over the past 12 months. Bristol Myers Squibb opened a large innovation hub in India. AstraZeneca has decided to hold onto Evrenzo in China and Korea while returning rights to FibroGen in the U.S.

Pharma 130

Pharma 130

Advertisement

European Pharmaceutical Review

FEBRUARY 29, 2024

Eligible individuals in England and Wales can access the first licensed treatment for amyloid light-chain (AL) amyloidosis on the NHS. The National Institute for Health and Care Excellence (NICE) recommended DARZALEX ® (daratumumab) plus VELCADE ® (bortezomib), cyclophosphamide and dexamethasone (DVCd) as an option for people newly diagnosed with the systemic form of the disease.

Pharmaceutical 105

Pharmaceutical Manufacturing Patients 105

Pharmaceutical Technology

FEBRUARY 29, 2024

LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.

FDA 105

FDA 105

pharmaphorum

FEBRUARY 29, 2024

On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies.

Education 105

Education Doctors Patients 105

Pharmaceutical Technology

FEBRUARY 29, 2024

Amyotrophic lateral sclerosis (ALS) is a swiftly advancing, fatal neurodegenerative condition marked by muscle weakness, atrophy, and spasticity.

98

98

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

pharmaphorum

FEBRUARY 29, 2024

Ironwood Pharma says phase 3 trial of apraglutide in short bowel syndrome (SBS) hit it main endpoint, but missed secondary outcomes weigh on its share price

Pharma 104

Pharma 104

Pharmaceutical Technology

FEBRUARY 29, 2024

The NHS has expedited the availability of the new drug, Belumosudil for cancer patients with chronic graft versus host disease (GVHD).

Patients 98

Patients 98

pharmaphorum

FEBRUARY 29, 2024

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for routine use by the NHS in England and Wales.

103

103

Pharmaceutical Technology

FEBRUARY 29, 2024

The US HHS Secretary called for state collaboration on a project to improve gene therapy access for sickle cell disease.

98

98

Advertisement

Distribution

pharmaphorum

FEBRUARY 29, 2024

Generic and biosimilar drugmaker Sandoz has agreed to pay $265 million to settle allegations of price-fixing in a Pennsylvania lawsuit.

102

102

European Pharmaceutical Review

FEBRUARY 29, 2024

Last year, in agreeing to acquire Reata Pharmaceuticals for $7.3 billion , Biogen gained rights to SKYCLARYS ® (omaveloxolone), the first approved treatment for the rare disease Friedreich’s ataxia. The Committee for Medicinal Products for Human Use (CHMP) recently recommended the approval of several therapies for rare diseases, including the first oral treatment against residual haemolytic anaemia in the rare blood disorder, paroxysmal nocturnal haemoglobinuria, as well as the first therapy to

Medicine 95

Medicine Patients Recruitment Pharmaceutical 95

Copyright Clearance Center

FEBRUARY 29, 2024

A joint statement from major international publishing bodies appeals to South Africa's National Assembly to vote down its copyright bill…

94

94

PharmaTimes

FEBRUARY 29, 2024

Approximately 80% of patients taking Remicade from diagnosis had symptoms controlled

Patients 87

Patients 87

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales